Lin, 2021 - Google Patents
Regulation of hematopoiesis and B-lymphocyte development by histone deubiquitinasesLin, 2021
View PDF- Document ID
- 5852652351207446635
- Author
- Lin Y
- Publication year
External Links
Snippet
Hematopoiesis, or the production of all blood cells from a rare population of hematopoietic stem cells (HSCs), is a tightly regulated process that replenishes our blood and immune systems throughout life. In the pool of blood cells, B cells are crucial in the adaptive immune …
- 210000003719 B-Lymphocytes 0 title abstract description 213
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Horton et al. | Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors | |
Gekas et al. | β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1 | |
Pham et al. | STAT5B N642H is a driver mutation for T cell neoplasia | |
Han et al. | Chromatin remodeling mediated by ARID1A is indispensable for normal hematopoiesis in mice | |
JP2019512271A (en) | T cell exhaustion state specific gene expression regulator and use thereof | |
Tooze | A replicative self-renewal model for long-lived plasma cells: questioning irreversible cell cycle exit | |
Kishimoto et al. | Molecular pathogenesis of follicular lymphoma | |
Lin et al. | Regulation of B lymphocyte development by histone H2A deubiquitinase BAP1 | |
Man et al. | p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia | |
Welsh et al. | Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma | |
AU2019269318A1 (en) | Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function | |
Lin | Regulation of hematopoiesis and B-lymphocyte development by histone deubiquitinases | |
WO2017049002A1 (en) | A humanized mouse model of de novo human acute myeloid leukemia with a matching human immune system | |
Li et al. | Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas | |
Suske et al. | Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia | |
Garton | Functions of ARID3a in multiple hematopoietic cell types | |
Van Thillo | Oncogenic cooperation in T-cell acute lymphoblastic leukemia: the role of TLX3 and TCF7-SPI1 | |
Kirkpatrick | The Role of ETV6 Germline Mutations in B Cell Development and Predisposition to Leukemia | |
Qiling | Hematopoietic Stem Cell Integrity Is Dependent on Znf143 Maintenance of Chromosome Structure | |
WO2023230507A2 (en) | Harnessing ikzf:beta-catenin complexes in the treatment of lymphocyte associated diseases or conditions | |
Krutein | Molecular genetics of myeloid malignancy predisposition: Insights into pathogenesis and therapeutic translation | |
Östlund | The Translocation t (7; 12)(q36; p13) in Childhood Acute Myeloid Leukemia | |
Rajagopalan | A Tale of Two Codons: Synergistic Mechanisms in Oncogenic Nras Induced Hematological Malignancies | |
Huang | Molecular pathology of splicing and transcription factor mutations in myelodysplastic syndromes | |
Lin et al. | Decreased RNA‐binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide |